Physician profile
Cameron Ditty
NPI 1902224819
$4,483.28
in general payments reported to CMS, 2019-2025
26 companies · $838 in 2025
The $838 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $161 · 2020: $341 · 2021: $712 · 2022: $992 · 2023: $757 · 2024: $682 · 2025: $838.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,277.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,360.01 | 2019-2025 | Rinvoq, Skyrizi, Mavyret |
| Takeda Pharmaceuticals U.S.A., INC. | $349.51 | 2020-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $331.41 | 2019-2024 | Trulance, Xifaxan |
| Gilead Sciences, INC. | $187.74 | 2020-2025 | |
| Pfizer INC. | $187.17 | 2020-2025 | |
| Janssen Biotech, INC. | $146.11 | 2020-2025 | Stelara, Tremfya |
| Genzyme Corporation | $134.84 | 2024-2025 | |
| Celgene Corporation | $122.79 | 2022-2023 | Zeposia |
| Intercept Pharmaceuticals, INC. | $103.64 | 2021-2023 | Ocaliva |
| Nestle Healthcare Nutrition INC. | $88.68 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $62.67 | 2020-2022 | |
| Olympus America INC. | $50.66 | 2021-2022 | |
| Madrigal Pharmaceuticals | $43.29 | 2024-2025 | Resmetirom, Rezdiffra |
| Medtronic, INC. | $42.73 | 2025 | Barrx, Pillcam |
| Qol Medical, LLC | $40.86 | 2021-2024 | Sucraid |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $29.77 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $28.53 | 2024 | Iqirvo, Bylvay |
| Merck Sharp & Dohme LLC | $26.08 | 2020-2022 | |
| Aimmune Therapeutics, INC. | $24.19 | 2025 | Zenpep |
| Lilly USA, LLC | $21.83 | 2024 | Omvoh |
| Endogastric Solutions, INC | $18.22 | 2023 | Esophyx |
| Daiichi Sankyo INC. | $17.93 | 2021 | |
| Phathom Pharmaceuticals, INC. | $17.31 | 2024 | Voquezna |
| Stryker Corporation | $16.27 | 2025 | Neptune |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.21 | 2023 | Cyltezo |
| Ardelyx, INC. | $14.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cameron Ditty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.